UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer ID No.) |
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
The | ||
The |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 12, 2023, Sunshine Biopharma, Inc. (the “Company”) held a special virtual meeting of the holders of its outstanding warrants issued by the Company on February 17, 2022 (the “Tradeable Warrants”). At the meeting, the holders approved an amendment to the Warrant Agent Agreement, dated February 17, 2022 (the “Warrant Agent Agreement”), between the Company and Equiniti Trust Company to (i) reduce the exercise price of the Tradeable Warrants to $0.11, subject to further adjustment as provided therein, and (ii) eliminate the provision under the Warrant Agent Agreement that prohibits the Company’s chief executive officer, Dr. Steve N. Slilaty, from exercising his voting rights under his Series B Preferred Stock of the Company. Holders of 736,242 Tradeable Warrants voted in favor of the amendment (representing 76.4% of 963,693 outstanding Tradeable Warrants), votes against were 62,429, and there were 3,930 abstentions.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 13, 2023 | SUNSHINE BIOPHARMA, INC. |
By: /s/ Dr. Steve N. Slilaty | |
Dr. Steve N. Slilaty, Chief Executive Officer |
3 |
-8?20$3;
M8T.P6BP^0"X99K>]9!:G
6T\*$JRS;R
M;1$:&S@L"V8O6 _2F4L98'.O%0527'+&3!WUQE'+.97?B^0>7/.;!O-.867\%B K58;X@L*[BBC++&R2UV"M%KD
M0Z:@O(XRROPDN]H$*\26&)[184.V6FR0,*BYHTSSI6-;-NJKEUWJJY<-^FI'
MF69.*IVHK\^[FSDE2P2O"*P(Z(3Z$&_("%N=WL*(=+V6>1^;B!)6UWK#;H$5
MVFKQ8<:@[*Z6PL8A43A,"5X3AEB@D[E=I8 [!'51[3:C"7G0%Z?/2;]C2G]G
M_)G-,)**NI!3.WW/5ZRYW:KJ9CSVC
9R=_L;_T+WI<(EH/&
MJ Y),80 TMQ)/^^:H\GEXHZ.J7*++>[IW%S:AA["4RE <6B@ZO%.*#"/DGB]
M;A4$VB8?[*>K3]P/]S\6V#-_ U!+ P04 " "$54U7A\! &?L2 :9P
M#P '-U;G-H:6YE7SAK+FAT;>T=:U?B2O*[Y_@?>KD[>YQS>23A)>BX!P$5
M'Z"BH\X73Y,TT&-(,IV$A[]^JSL))!!45)R9NW/W7I5T=75UO:NZR>[^=SS0
MT9 PFYK&EX2;[,KQN'.!B/<&&!H7YN$,H$
MO,0DR+YV,S ??O/_[5JK9GH[:(!9CQIEQ$&E'<25,85UVH-'*A@2=TB[G;WK
M9N.J7D/MJ\I5O;V;Z4#Q8^VM
'WW(W@]&Q@IO6(;F[:!I6[?)KGS8RY[E^KU3)_GTRT;XIMZ7M
M